NL-OMON36951已完成2 期
A phase II study of Vorinostat in patients with Polycythaemia Vera and Essential Thrombocythaemia - Vorinostat in PV and ET
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •PV: 11. Male or female patient > 18 years of age and 2. A confirmed diagnosis of PV (see appendix 1) and 3. Biochemical evidence of active disease as defined by a) A need for phlebotomy within the last 3 months b) a leukocyte count > 10 x 109/L in the absence of infection or inflammation (normal CRP) and/or (PV/ET) c) a platelet count > 450 x 109/L in the absence of infection or inflammation (normal CRP) (PV/ET). ET: 1. Male or female patient > 18 years of age and 2. A confirmed diagnosis of high risk ET (see appendix 1) and 3. Biochemical evidence of active disease as defined by a) a platelet count > 450 x 109/L in the absence of infection or inflammation (normal CRP). PV + ET: 1. Newly diagnosed or previously treated patients in chronic phase or 2. Advanced phase PV or ET as defined by blasts of > 1 x 109/L in the peripheral blood and/or white cell count > 30 x 109/L or 3. Resistant or refractory PV or ET as defined by a haemoglobin < 10.5gm/dl with a platelet count > 600 x 109/L on current therapy or 4. Cycling platelet counts on therapy or 5. Intolerant to other therapies defined by patients with PV or ET who have side effects on current therapies preventing continuation (leg ulcers on hydroxycarbamide, unacceptable fatigue etc on interferon).
排除标准
- •1. A platelet count > 1500 x 109/L (a need for cytoreduction in platelet count) 2. Patients of childbearing potential without a negative pregnancy test prior to initiation of study drug. 3. Women who are breast feeding 4. Males and females not using contraceptives if sexually active. It is recommended that 2 reliable forms of contraception be used simultaneously unless abstinence is the chosen method of contraception. Non-pregnant, non-breast-feeding women may be enrolled if they are considered highly unlikely to conceive. Highly unlikely to conceive is defined as (a) surgically sterilized, or (b) postmenopausal, or (c) not heterosexually active for the duration of the study, or (d) heterosexually active and willing to use 2 birth control methods. The 2 birth control methods can be either 2 barrier methods or a barrier method plus a hormonal method to prevent pregnancy, used throughout the study starting with Visit 1. A woman who is ???45 years of age and has not had menses for greater than 2 years will be considered postmenopausal. 5. ECOG Performance Status Score ??? 3 6. Serum creatinine more than 2 x???s the ULN 7. Total serum bilirubin more than 1.5 x???s the ULN 8. Serum AST/ALT more than 3 x???s the ULN 9. Interferon alpha within 1 week of day 1 10. Hydroxycarbamide within 1 week of day 1 11. Anagrelide within 1 week of day 1 12. Valproic acid (as an anticonvulsant) within 28 days of day 1 13. Any other investigational drug within 28 days of day 1 14. Active HIV, HBV or HCV infection. 15. Any serious concomitant disease or circumstances that could limit compliance with the study, including but not limited to the following: CTCAE grade 3-4 cardiac general & arrhythmia, or psychiatric or social conditions that may interfere with patient compliance. 16. Any prior malignancy with the exception of cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or other localized malignancy that has undergone potentially curative therapy with no evidence of that disease for five years, and who is deemed to be at low risk for recurrence by his/her treating physician. 17. Patient has a known allergy or hypersensitivity to vorinostat capsules.
研究者
相似试验
进行中（未招募）
1 期
A phase II study of Vorinostat in patients with Polycythaemia Vera and Essential Thrombocythaemiapatients with polycythemia vera and essential thrombocythaemiaMedDRA version: 9.1Level: LLTClassification code 10036061Term: Polycythemia veraMedDRA version: 9.1Level: LLTClassification code 10015494Term: Essential thrombocythemiaEUCTR2007-005306-49-NLVUmc60
进行中（未招募）
不适用
A Phase II Study of Vorinostat in Patients with Polycythaemia Vera and Essential Thrombocythaemiapatients with polycythaemia vera or essential thrombocythaemia or myelofibrosisMedDRA version: 9.1Level: LLTClassification code 10036057Term: Polycythaemia veraMedDRA version: 9.1Level: LLTClassification code 10015493Term: Essential thrombocythaemiaMedDRA version: 12.1Level: LLTClassification code 10028537Term: MyelofibrosisEUCTR2007-005306-49-DKDepartment of Haematology, Herlev Hospital, University of Copenhagen80
进行中（未招募）
不适用
A Phase II Study of Vorinostat in Patients with Polycythaemia Vera and Essential ThrombocythaemiaEUCTR2007-005306-49-SEDepartment of Haematology, Herlev Hospital, University of Copenhagen60
进行中（未招募）
1 期
A Phase II Study Of Vorinostat (MK-0683) In Patients With Polycythaemia Vera And Essential Thrombocythaemia - Vorinostat (MK0683)The myeloproliferative disorders (MPDs) polycythaemia vera (PV) and essential thrombocythaemia (ET) are chronic haematological malignancies associated with increased risk of thrombosis, haemorrhage and leukaemic transformation. Recently an acquired mutation in JAK 2 has been described in >95% of patients with PV and 50% with ET.EUCTR2007-005306-49-GBHerlev Hospital
进行中（未招募）
不适用
A Phase I/II Study of Vorinostat in Combination with Low Dose Ara-C for Patients with Intermediate-2 or High Risk Myelodysplastic Syndromes - GFM-VOR-2007-1EUCTR2007-002212-26-FRGroupe Francophone des Myélodysplasies